Cargando…
Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
BACKGROUND: The value of anti-angiogenesis antibody therapy in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) remains unknown. We carried out a phase II study to evaluate the addition of bevacizumab to paclitaxel plus carboplatin in R/M NPC. MATERIALS AND METHODS: A total of 80 patients...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637468/ https://www.ncbi.nlm.nih.gov/pubmed/34837744 http://dx.doi.org/10.1016/j.esmoop.2021.100313 |
_version_ | 1784608746909990912 |
---|---|
author | Zhou, T. Yang, Y. Ma, S. Lin, L. Zhou, T. Zhang, C. Ding, X. Wang, R. Feng, G. Chen, Y. Xu, R. Huang, Y. Zhang, L. |
author_facet | Zhou, T. Yang, Y. Ma, S. Lin, L. Zhou, T. Zhang, C. Ding, X. Wang, R. Feng, G. Chen, Y. Xu, R. Huang, Y. Zhang, L. |
author_sort | Zhou, T. |
collection | PubMed |
description | BACKGROUND: The value of anti-angiogenesis antibody therapy in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) remains unknown. We carried out a phase II study to evaluate the addition of bevacizumab to paclitaxel plus carboplatin in R/M NPC. MATERIALS AND METHODS: A total of 80 patients with previously untreated R/M NPC were randomly assigned (1 : 1) to CPB or CP groups to receive carboplatin (area under the curve 6) and paclitaxel (175 mg/m(2)) intravenously every 3 weeks for a maximum of six cycles in combination with or without bevacizumab (7.5 mg/kg), respectively. The primary endpoint was progression-free survival (PFS) as per investigators, and the secondary endpoints were PFS as per independent review committee (IRC), overall survival (OS), objective response rate (ORR), and safety. This study was registered with ClinicalTrials.gov (NCT02250599). RESULTS: The median PFS as per investigators was 7.5 months [95% confidence interval (CI), 6.53-8.45 months] in the CPB group and 6.5 months (95% CI, 5.53-7.52 months) in the CP group (P = 0.148), which were similar to IRC-assessed PFS. The median OS was also alike between CPB and CP arms (21.0 versus 24.7 months; P = 0.326). ORRs were 87.2% and 72.5%, respectively (P = 0.105). However, the tumor-shrinking rate was higher in the CPB arm than in the CP arm (P = 0.035). No differences in grade 3 or higher adverse events between the groups were observed. CONCLUSIONS: Addition of bevacizumab to paclitaxel plus carboplatin as first-line treatment did not prolong PFS and OS in patients with R/M NPC but improved tumor-shrinking rate. These results indicated that bevacizumab plus chemotherapy might be an optional choice for NPC with heavy tumor load or those pursuing short-term efficacy in neoadjuvant and concurrent chemotherapy. |
format | Online Article Text |
id | pubmed-8637468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86374682021-12-09 Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial Zhou, T. Yang, Y. Ma, S. Lin, L. Zhou, T. Zhang, C. Ding, X. Wang, R. Feng, G. Chen, Y. Xu, R. Huang, Y. Zhang, L. ESMO Open Original Research BACKGROUND: The value of anti-angiogenesis antibody therapy in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) remains unknown. We carried out a phase II study to evaluate the addition of bevacizumab to paclitaxel plus carboplatin in R/M NPC. MATERIALS AND METHODS: A total of 80 patients with previously untreated R/M NPC were randomly assigned (1 : 1) to CPB or CP groups to receive carboplatin (area under the curve 6) and paclitaxel (175 mg/m(2)) intravenously every 3 weeks for a maximum of six cycles in combination with or without bevacizumab (7.5 mg/kg), respectively. The primary endpoint was progression-free survival (PFS) as per investigators, and the secondary endpoints were PFS as per independent review committee (IRC), overall survival (OS), objective response rate (ORR), and safety. This study was registered with ClinicalTrials.gov (NCT02250599). RESULTS: The median PFS as per investigators was 7.5 months [95% confidence interval (CI), 6.53-8.45 months] in the CPB group and 6.5 months (95% CI, 5.53-7.52 months) in the CP group (P = 0.148), which were similar to IRC-assessed PFS. The median OS was also alike between CPB and CP arms (21.0 versus 24.7 months; P = 0.326). ORRs were 87.2% and 72.5%, respectively (P = 0.105). However, the tumor-shrinking rate was higher in the CPB arm than in the CP arm (P = 0.035). No differences in grade 3 or higher adverse events between the groups were observed. CONCLUSIONS: Addition of bevacizumab to paclitaxel plus carboplatin as first-line treatment did not prolong PFS and OS in patients with R/M NPC but improved tumor-shrinking rate. These results indicated that bevacizumab plus chemotherapy might be an optional choice for NPC with heavy tumor load or those pursuing short-term efficacy in neoadjuvant and concurrent chemotherapy. Elsevier 2021-11-24 /pmc/articles/PMC8637468/ /pubmed/34837744 http://dx.doi.org/10.1016/j.esmoop.2021.100313 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Zhou, T. Yang, Y. Ma, S. Lin, L. Zhou, T. Zhang, C. Ding, X. Wang, R. Feng, G. Chen, Y. Xu, R. Huang, Y. Zhang, L. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial |
title | Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial |
title_full | Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial |
title_fullStr | Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial |
title_full_unstemmed | Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial |
title_short | Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial |
title_sort | bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase ii trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637468/ https://www.ncbi.nlm.nih.gov/pubmed/34837744 http://dx.doi.org/10.1016/j.esmoop.2021.100313 |
work_keys_str_mv | AT zhout bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT yangy bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT mas bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT linl bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT zhout bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT zhangc bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT dingx bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT wangr bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT fengg bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT cheny bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT xur bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT huangy bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial AT zhangl bevacizumabversusplaceboincombinationwithpaclitaxelandcarboplatinasfirstlinetreatmentforrecurrentormetastaticnasopharyngealcarcinomaamulticentrerandomisedopenlabelphaseiitrial |